Anavex Life Sciences Corp (AVXL)

[Joseph_K]

A little help on the PR stats?

... the differences in the least-squares mean (LSM) change from baseline to 48 weeks between the blarcamesine and placebo groups were -1.783 [95% CI, -3.314 to -0.251]; (P = 0.0226) for ADAS-Cog13, and -0.456 [95% CI, -0.831 to -0.080]; (P = 0.0175) for CDR-SB in patients with early Alzheimer’s disease.

I get least-squares mean change, confidence interval, and p- value. I'll explain the part I don't understand with respect to ADAS-Cog13.

The PR says that the difference in the least-squares mean change from baseline to 48 weeks between the blarcamesine and placebo groups was -1.783 [95% CI, -3.314 to -0.251]. Is -1.783 the difference over that period between the amounts changed by the drugged and placebo groups in terms of the point scores on ADAS-Cog? I think I'm accustomed to seeing this information as a percentage in slowing of decline: Is there enough info here to derive that percentage? Or to compare this result in the PR to (for example) lecanemab's percentage of slowing of decline?

How does [-3.314 to -0.251] for ADAS-Cog fit into this?